Anatomical, physiological, and experimental factors affecting the bioavailability of Sc-Administered large biotherapeutics

Journal of Pharmaceutical Sciences

Volumn 104, Issue 2, 2015, Pages 301-306

  Fathallah, Anas M ^a   Balu Iyer, Sathy V ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Absorption; Bioavailability; Biotechnology; Preclinical pharmacokinetics; Proteins

Indexed keywords

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG UPTAKE; EXTRACELLULAR MATRIX; HEALTH CARE COST; IMMUNOTHERAPY; INFECTION RISK; LYMPH VESSEL; MEDICATION COMPLIANCE; PHYSICAL CHEMISTRY; PROTEIN DEGRADATION; PROTEIN TRANSPORT; QUALITY OF LIFE; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; BIOAVAILABILITY; BIOLOGICAL THERAPY; HUMAN; METABOLISM;

BIOLOGICAL PRODUCT;

BIOLOGICAL AVAILABILITY; BIOLOGICAL PRODUCTS; BIOLOGICAL THERAPY; HUMANS; INJECTIONS, SUBCUTANEOUS;

EID: 84922933549     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24277     Document Type: Note

References (38)

1. Leader B, Baca QJ, Golan DE. 2008. Protein therapeutics: A summary and pharmacological classification. Nat Rev Drug Discov 7(1):21-39.
2. Bookbinder LH, Hofer A, Haller MF, Zepeda ML, Keller GA, Lim JE, Edgington TS, Shepard HM, Patton JS, Frost GI. 2006. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release 114(2):230-241.
3. Frost GI. 2007. Recombinant human hyaluronidase (rHuPH20): An enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv 4(4):427-440.
4. Richter WF, Bhansali SG, Morris ME. 2012. Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J 14(3):559-570.
5. Sarah Y. Yuan and Robert R. Rigor. 2010. Structure and function of exchange microvessels. Regulation of Endothelial Barrier Function. San Rafael (CA): Morgan & Claypool Life Sciences.
6. Swartz MA. 2001. The physiology of the lymphatic system. Adv Drug Deliv Rev 50(1,AI2):3-20.
7. Sarin H. 2010. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J Angiogenes Res 2(14):14.
8. Jones EA, Waldmann TA. 1972. The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat. J Clin Invest 51(11):2916-2927.
9. Dickinson BL, Badizadegan K, Wu Z, Ahouse JC, Zhu X, Simister NE, Blumberg RS, Lencer WI. 1999. Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest 104(7):903-911.
10. Claypool SM, Dickinson BL, Wagner JS, Johansen FE, Venu N, Borawski JA, Lencer WI, Blumberg RS. 2004. Bidirectional transepithelial IgG transport by a strongly polarized basolateral membrane Fcgamma-receptor. Mol Biol Cell 15(4):1746-1759.
11. Ghetie V, Hubbard JG, Kim JK, Tsen MF, Lee Y, Ward ES. 1996. Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol 26(3):690-696.
12. Junghans RP, Anderson CL. 1996. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci USA 93(11):5512-5516.
13. Tzaban S, Massol RH, Yen E, Hamman W, Frank SR, Lapierre LA, Hansen SH, Goldenring JR, Blumberg RS, Lencer WI. 2009. The recycling and transcytotic pathways for IgG transport by FcRn are distinct and display an inherent polarity. J Cell Biol 185(4):673-684.
14. Kagan L, Turner MR, Balu-Iyer SV, Mager DE. 2012. Subcutaneous absorption of monoclonal antibodies: Role of dose, site of injection, and injection volume on rituximAb pharmacokinetics in rats. Pharm Res 29:9.
15. Khawli LA, Goswami S, Hutchinson R, Kwong ZW, Yang J, Wang X, Yao Z, Sreedhara A, Cano T, Tesar D, Nijem I, Allison DE, Wong PY, Kao YH, Quan C, Joshi A, Harris RJ, Motchnik P. 2010. Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats. mAbs 2(6):613-624.
16. Igawa T, Tsunoda H, Tachibana T, Maeda A, Mimoto F, Moriyama C, Nanami M, Sekimori Y, Nabuchi Y, Aso Y, Hattori K. 2010. Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel 23(5):385-392.
17. Devenny JJ, Wagner RC. 1985. Transport of immunoglobulin G by endothelial vesicles in isolated capillaries. Microcirc Endothelium Lymphatics 2(1):15-26.
18. Hong G, Chappey O, Niel E, Scherrmann JM. 2000. Enhanced cellular uptake and transport of polyclonal immunoglobulin G and fab after their cationization. J Drug Target 8(2):67-77.
19. Negrini D, Moriondo A. 2011. Lymphatic anatomy and biomechanics. J Physiol 589(Pt 12):2927-2934.
20. Reddy ST, Berk DA, Jain RK, Swartz MA. 2006. A sensitive in vivo model for quantifying interstitial convective transport of injected macromolecules and nanoparticles. J Appl Physiol 101(4):1162-1169.
21. Xie DD, Hale V. 1996. Factors affecting the lymphatic absorption of macromolecules following extravascular administration. Pharm Res 13p S396
22. Bocci V, Muscettola M, Grasso G, Magyar Z, Naldini A, Szabo G. 1986. The lymphatic route. 1) Albumin and hyaluronidase modify the normal distribution of interferon in lymph and plasma. Experientia 42(4):432-433.
23. Bocci V, Muscettola M, Naldini A. 1986. The lymphatic route-III. Pharmacokinetics of human natural interferon-beta injected with albumin as a retarder in rabbits. Gen Pharmacol 17(4):445-448.
24. Porter CJ, Edwards GA, Charman SA. 2001. Lymphatic transport of proteins after s.c. injection: Implications of animal model selection. Adv Drug Deliv Rev 50(1-2):157-171.
25. Fathallah AM, Turner MR, Mager DE, Balu-Iyer SV. 2014. Forthcoming. Effects of hypertonic buffer composition on lymph node uptake and bioavailability of rituximab after subcutaneous administration. Biopharm Drug Dispos.doi: 10.1002/bdd.1925
26. Parsons JA, Rafferty B, Stevenson RW, Zanelli JM. 1979. Evidence that protease inhibitors reduce the degradationofparathyroid hormone and calcitonin injected subcutaneously. Br J Pharmacol 66(1):25-32.
27. Mager DE, Neuteboom B, Efthymiopoulos C, Munafo A, Jusko WJ. 2003. Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta1a in monkeys. J Pharmacol Exp Ther 306(1):262-270.
28. Fathallah AM, Bankert RB, Balu-Iyer SV. 2013. Immunogenicity of subcutaneously administered therapeutic proteins - A mechanistic perspective. AAPS J 15:897-900.
29. Langenkamp A, Messi M, Lanzavecchia A, Sallusto F. 2000. Kinetics of dendritic cell activation: Impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol 1(4):311-316.
30. Hwang ST. 2012. Homeward bound: How do skin dendritic cellsfind their way into the lymph system? J Invest Dermatol 132(4):1070-1073.
31. McDonald TA, Zepeda ML, Tomlinson MJ, Bee WH, Ivens IA. 2010. Subcutaneous administration of biotherapeutics: Current experience in animal models. Curr Opin Mol Ther 12(4):461-470.
32. Swindle MM. Nov. 12 2014. Porcine integumentary system models: Part 1 - Dermal toxicology. Accessed, at: http://www.sinclairresearch.com.
33. Swindle MM, Makin A, Herron AJ, Clubb FJ Jr, Frazier KS. 2012. Swine as models in biomedical research and toxicology testing. Vet Pathol 49(2):344-356.
34. Eaglstein WH, Mertz PM. 1978. New methods for assessing epidermal wound healing: The effects of triamcinolone acetonide and polyethelene film occlusion. J Invest Dermatol 71(6):382-384.
35. McFarlin DE, Binns RM. 1973. Lymph node function and lymphocyte circulation in the pig. Adv Exp Med Biol 29(0):87-93.
36. Zheng Y, Tesar DB, Benincosa L, Birnbock H, Boswell CA, Bumbaca D, Cowan KJ, Danilenko DM, Daugherty AL, Fielder PJ, Grimm HP, Joshi A, Justies N, Kolaitis G, Lewin-Koh N, Li J, McVay S, O'Mahony J, Otteneder M, Pantze M, Putnam WS, Qiu ZJ, Ruppel J, Singer T, Stauch O, Theil FP, Visich J, Yang J, Ying Y, Khawli LA, Richter WF. 2012. Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration. mAbs 4(2):243-255.
37. Swabb EA, Wei J, Gullino PM. 1974. Diffusion and convection in normal and neoplastic tissues. Cancer Res 34(10):2814-2822.
38. Kang DW, Oh DA, Fu GY, Anderson JM, Zepeda ML. 2013. Porcine model to evaluate local tissue tolerability associated with subcutaneous delivery of protein. J Pharmacol Toxicol Methods 67(3):140-147.